Viridian Therapeutics, Inc.\DE (VRDN) Profit After Tax (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Profit After Tax history runs 14 years deep, the most recent figure standing at -$105.9 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 22.21% year-over-year to -$105.9 million in Q1 2026; TTM through Mar 2026 was -$18.9 million, a 93.87% increase from a year earlier, with the FY2025 full-year figure at $457000.0, up 100.17% from the prior year.
• Profit After Tax retreated to -$105.9 million in Q1 2026 per VRDN's latest filing, from $222.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at $222.3 million in Q4 2025 and bottomed at -$129.1 million in Q4 2022.
• The 5-year median for Profit After Tax is -$65.0 million (2024), against an average of -$46.9 million.
• Across the five-year window, Profit After Tax soared 1422.22% in 2022 and plunged 34808.76% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$129.1 million in 2022, then jumped by 48.21% to -$66.9 million in 2023, then decreased by 20.13% to -$80.3 million in 2024, then soared by 376.81% to $222.3 million in 2025, then plunged by 147.63% to -$105.9 million in 2026.
• Per Business Quant, the three latest VRDN Profit After Tax figures stand at -$105.9 million (Q1 2026), $222.3 million (Q4 2025), and -$34.6 million (Q3 2025).